While CSF pTau in ALS is also lower than that in healthy controls [31], recent evidence has demonstrated that phospho-tau species (pTau181, pTau217) are elevated in the sera of ALS patients as well, challenging the disease specificity of these canonical AD markers, if applied without clinical context [17]. The gene discussed is MAPT; the disease is Alzheimer disease.